<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4: Drugs That May Alter Hepatic Metabolism of T<sub>4</sub> (Hypothyroidism)</caption>
<col align="left" valign="top" width="40%"></col>
<col align="left" valign="top" width="60%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule">Drug or Drug Class</th>
<th align="center" stylecode="Rrule">Effect</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="2">Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine requirements.</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Carbamazepine<br/>Hydantoins</td>
<td stylecode="Rrule">Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and FT4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Close monitoring of thyroid hormone parameters is recommended.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Other drugs:<br/>Phenobarbital<br/>Rifampin</td>
<td stylecode="Rrule"></td>
</tr>
</tbody>
</table>